Patent waiver seen stalling vaccine production in Nigeria

COVAX has secured enough vaccines to achieve 45 percent of coverage across countries by the middle of this year

The refusal to waive intellectual property (IP) rights by pioneering manufacturers of COVID-19 vaccines could pose a setback to the adoption of the mRNA vaccine production technology Nigeria and some other African countries are set to receive. The technology transfer could fail to realise the goa

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```